Teclistamab + Pomalidomide for Multiple Myeloma

This trial explores whether combining two new drugs, teclistamab and pomalidomide, can better treat relapsed multiple myeloma compared to a standard treatment that includes carfilzomib. Teclistamab is a specialized antibody that targets and disrupts cancer cell growth, while pomalidomide enhances the immune system to combat cancer. Participants will be divided into different groups to compare these treatments. The trial seeks patients whose multiple myeloma has returned after previous treatments and who have already tried certain standard therapies. As a Phase 1/Phase 2 trial, this research aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group, offering participants a chance to contribute to groundbreaking cancer treatment advancements.

Previous studies have identified some safety concerns with teclistamab, such as infections and cytokine release syndrome (CRS), occurring in about 54% and 60% of patients, respectively. CRS can cause fever and flu-like symptoms. Despite these issues, many patients continued treatment without severe problems. Pomalidomide, when used in combinations, has been considered well-tolerated, with no major safety issues reported.

Researchers are excited about these treatments for multiple myeloma because they incorporate teclistamab, a bispecific antibody that targets both BCMA and CD3, offering a novel approach compared to traditional treatments like lenalidomide and bortezomib. This unique mechanism allows the immune system to better identify and attack cancer cells. Additionally, teclistamab is administered subcutaneously, which may improve patient convenience and adherence compared to intravenous options. The combination with pomalidomide, an existing immunomodulatory drug, further enhances the potential to tackle multiple myeloma more effectively.

This trial will evaluate the effectiveness of different treatment combinations for multiple myeloma. In one arm, patients will receive a combination of carfilzomib, pomalidomide, and dexamethasone. Studies have shown that using teclistamab with other drugs appears very promising for treating multiple myeloma, a type of blood cancer. In other arms of this trial, patients will receive teclistamab and pomalidomide. Teclistamab helps the immune system attack cancer by attaching to specific proteins on both the cancer cells and T-cells, a type of immune cell. Research shows that this combination can reduce the risk of disease progression or death by 83% when used with certain other treatments. Patients have responded well, with many experiencing complete responses and longer periods without disease worsening. Pomalidomide, when used with teclistamab, further boosts the immune system to effectively target cancer cells. Together, these drugs have the potential to improve outcomes for patients whose multiple myeloma has returned.²⁴⁵⁶⁷